SPOTLIGHT: Starpharma acquires Dendritic Nanotechnologies

Starpharma has struck a deal to buy all the stock of Dendritic Nanotechnologies it doesn't already own for about $7 million in Starpharma shares. DNT CEO Dr. Robert Berry will stay with the company, which becomes a wholly owned subsidiary with its operations remaining in Mount Pleasant, MI. Dendritic has been developing new dendrimer technology, which can be used as both a diagnostic tool as well as a new delivery vehicle to deliver targeted therapeutics. Two days ago DNT won a $850,000 SBIR grant for its work in cancer. Release

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.